Bruker Announces AVANCE™-IVDr as a Standardized NMR Platform for Clinical Screening & In Vitro Diagnostics (IVD) Discovery ...
22 July 2013 - 9:00PM
Business Wire
Bruker today announces a standardized nuclear magnetic resonance
(NMR) spectroscopy platform for its clinical and diagnostics
partners that enables cost-effective, high-performance NMR clinical
screening and IVD-by-NMR discovery, development and validation of
novel NMR assays.
Surgeons with two new AVANCE 600 MHz NMR
systems at the Imperial/St. Mary's Clinical Phenome Center (London,
UK) (Photo: Business Wire)
The new AVANCE-IVDr system, presently for research use
only, is a complete, proven and standardized platform for NMR
clinical research and screening, as well as for IVD-by-NMR
research. It features high sensitivity and information-rich output
at 600 MHz proton-NMR frequency, and incorporates advanced
hardware, software, automation, spectral libraries and standard
operating procedures (SOPs) for high-performance bio-fluid
screening and assay validation. Customer benefits include higher
information content and spectral feature differentiation compared
to low-field NMR systems, as well as excellent reproducibility,
high throughput and potentially dramatically lower cost per sample
for better clinical screening and IVD-by-NMR.
Dedicated to NMR-based clinical screening and diagnostics, the
AVANCE-IVDr is optimized for ease-of-use and highest data
quality and reliability. The new standardized platform offers
barcode analysis, control by a LIMS system, the high-throughput,
temperature-controlled autosampler SampleJet™, remote
access, and automatic analysis and customizable analytical results
reporting. Based on Bruker-validated SOPs, the AVANCE-IVDr
platform enables the development of diagnostic tools for
body-fluids, or even biopsy samples, that can address a variety of
medical questions. The SOPs guarantee the production of highly
reproducible clinical data, enabling the exchange and validation of
novel NMR assays between laboratories on a global basis. In a
translational clinical research environment the results produced by
these NMR assays can easily be transferred into clinical screening
and future IVD use.
Bruker’s NMR spectroscopy systems are already in use in more
than forty clinical research centers worldwide, including hospitals
working on modern health-related screening techniques, such as
human metabonomics. The AVANCE-IVDr system in its latest,
standardized configuration has been installed already at several
customer and strategic partner sites. Cross calibrations performed
by Bruker across several centers have demonstrated NMR’s unique
advantage that spectra from samples prepared and measured under the
Bruker SOPs are identical, independent of a center’s location or
operating staff.
As a result of a long-standing collaboration with Imperial
College London, the AVANCE-IVDr platform is already enabling
the analysis of over 100,000 samples per year at the UK’s recently
opened MRC-NIHR Phenome Centre. This level of large-scale
health-related NMR screening is paving the way for worldwide
epidemiological studies as well as for clinical research and
diagnosis. The benefits have been significant: facilitated by the
low cost per sample and the even lower cost per parameter as
compared to established single parameter screening methods, novel
NMR methods for determining the cause of disease, delivering
individualized patient treatment and developing strategies for
prevention are now available to many clinical researchers.
Professor Jeremy Nicholson, Director of the MRC-NIHR Phenome
Centre and Head of the Department of Surgery and Cancer at Imperial
College London, commented: “The latest generation of Bruker NMR
instruments gives us staggering day to day and long term
reproducibility and reliability of spectral acquisition, coupled
with the ability to do automated digital quantification of multiple
metabolites. Thus, uniquely, the NMR technology platform can be
used in simultaneous exploratory and targeted modes. We are totally
committed to the use of NMR spectroscopy (in association with mass
spectrometry) as a definitive bio-screening tool, and the latest
technology developments now allow the deployment of the platform on
an industrial scale.”
Dr. Manfred Spraul, Bruker’s Director of Applied NMR Business
Development, added: “Migrating from translational research to
clinical diagnostics requires robust, identical instrumentation in
research facilities and hospitals, which is why Bruker has decided
to offer the standardized AVANCE-IVDr platform, enabling a
smooth transfer from health research and large epidemiological
studies, to our partners’ emerging IVD assays at the highest
quality and reproducibility. With modern NMR technology and the
right SOPs, we and our collaborators have opened the path to
complex mixture analysis using push-button technology, establishing
NMR as one of the two major technologies used in metabolic
profiling and screening.”
About Bruker Corporation
Bruker Corporation (NASDAQ: BRKR) is a leading provider of high
performance scientific instruments and solutions for molecular and
materials research, as well as industrial, diagnostics and applied
analysis.
For more information, please visit www.bruker.com
Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20130722005122/en/
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024